Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PCI-24781 Administered Orally in Patients With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Abexinostat (Primary)
- Indications Chronic lymphocytic leukaemia; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Pharmacyclics
- 26 Sep 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 26 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Planned end date changed from 1 Sep 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.